Search Results for: multiple myeloma

Multiple Myeloma Treatment Advances: Five Things to Know 

by

For patients with multiple myeloma, a treatable but incurable cancer that affects blood plasma cells, there are many new options for treatment that are producing better, and increasingly long-lasting outcomes.   There are also therapies under investigation that show similar promise for patients with relapsed/refractory multiple myeloma, newly diagnosed multiple myeloma, and a pre-cancerous condition called smoldering myeloma, with a beneficial impact felt across the whole spectrum of disease.  “This is a … Read more

Cancer Conversations Podcast – Episode #4: The Latest Research in Multiple Myeloma and Leukemia

by

With new research in immunotherapy and targeted therapy, treatment options for blood cancer patients are rapidly expanding. Combination therapies have also caused much excitement among researchers and physicians, and ongoing clinical trials are continuing to look at new strategies that use multiple drugs for fighting these diseases. In this Cancer Conversations podcast episode, Irene Ghobrial, … Read more

The Latest Research in Multiple Myeloma, Leukemia and Other Blood Cancers

by

The last two years have been very exciting for blood cancer research; many new targeted therapies and immunotherapies are improving treatment outcomes for patients with lymphoma, leukemia and multiple myeloma. “We’re starting to see a lot of hematologic malignancies benefit from immunotherapy,” says Irene Ghobrial, MD. “The excitement is there for so many trials and … Read more

Remembering My Father’s Journey with Multiple Myeloma

by

By Elise Renner There’s a 1-in-12 chance that this is the month yours or your loved one’s cancer is recognized—odds better than the survival rates for some of these diseases. Some months, like October, boast big names like breast cancer. Others, like September, are crowded with lesser-known branches of the disease. “Cancer apparel,” including ribbons … Read more

Research Advances Hold Promise for Multiple Myeloma Treatment

by

Multiple myeloma is one of the most compelling examples of a cancer in which research has markedly improved the length and quality of patients’ lives in the last decade. A malignancy of certain white blood cells in the bone marrow known as plasma cells, myeloma is still considered incurable, but treatment advances have significantly improved survival. … Read more

CAR T-Cell Therapy Delivers a Revelatory Experience for Myeloma Patient 

by

Linda Lane was still fatigued months after having COVID-19 in January of 2021.   “I told my doctor that I had not been this tired since I had a newborn in the house,” says Lane, now 57 and living on Cape Cod. “That got her attention.”  Her bloodwork came back with abnormal results. By May, the … Read more

Patient is First at Dana-Farber to Undergo Outpatient Stem Cell Transplant for Myeloma 

by

In most ways, Bill Ross’s stem cell transplant for multiple myeloma at Dana-Farber Brigham Cancer Center (DFBCC) wasn’t out of the ordinary. He received chemotherapy to destroy the tumor cells in his body and then an infusion of his own hematopoietic stem cells, which flocked to his bone marrow and regenerated his blood supply. Over … Read more

Advances in Myeloma, Breast Cancer, and Clinical Trials Equity: A Dana-Farber Research Update

by

Results of several phase 3 trials and dozens of other studies led by Dana-Farber researchers were presented online and in person June 3-7 at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), the world’s largest clinical cancer research meeting. Some of the research reports presented by Dana-Farber investigators include: Improved progression-free … Read more

For Sisters, Myeloma Study is a Promise Kept

by

At Carolyn Kershaw and Darlene Musso’s first visit to Dana-Farber in July, Irene Ghobrial, MD, greeted them with some unexpected news. “We walked in and she said, ‘Did you know you two are famous in our lab?’” Kershaw recounts. Their local renown stems from their participation in the PROMISE study at Dana-Farber’s Center for the Prevention of Progression (CPOP), which … Read more

New Drug Regimens Show Promise in Early and Late Myeloma

by

Treatment advances for multiple myeloma continue to bring improved outcomes for patients in different stages of their disease. Recent clinical trial reports show progress in treating two myeloma populations — newly diagnosed, transplant eligible patients, and individuals whose disease has progressed following several lines of therapy. In one trial, the phase 2 GRIFFIN study showed … Read more

Cancer Patient Faces Multiple Diagnoses with the Strength of a Warrior

by

One bout of cancer is enough to contend with, but since 2014 Mary Johnson has had to cope with four different cancers and related conditions. Despite these tests of her physical and emotional strength, Johnson is doing well today after treatment at Dana-Farber. “Coming to Dana-Farber gave me confidence because they supported me, and I … Read more

Approval of Myeloma Drug Improves Patients’ Prospects

by

Five years into his treatment for multiple myeloma, Mark Young was attending a Dana-Farber conference to learn about the latest research in the disease when his oncologist — Paul Richardson, MD, clinical program leader and director of clinical research at the Institute’s Jerome Lipper Multiple Myeloma Center — came running up with some timely news. … Read more

New Drug Benefits Patients With Myeloma Who Are Resistant to All Therapies

by

Earlier this year, a novel drug became the first agent to receive U.S. Food and Drug Administration (FDA) approval for patients with multiple myeloma who have exhausted all types of currently available therapies, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. A clinical trial found that 26.2 percent of such patients responded with significant shrinkage … Read more

Myeloma Study Makes the Case for a New Standard for Predicting Long-Term Outcome

by

As new treatments for multiple myeloma have extended patient survival—from an average of three years to more than 10 in some cases—physicians and researchers face a new challenge: how to predict a drug’s long-term effectiveness? How to tell, early on, whether one drug is likely to extend patients’ lives more than another? At Dana-Farber’s Jerome Lipper … Read more